News
Public · Published
BPCL, HPCL, Asian Paints gain over 2% as Brent crude slips below $110; IndiGo, SpiceJet advance
In Monday morning trade, BPCL, HPCL and Asian Paints each gained more than 2%, while IndiGo and SpiceJet also advanced as Brent crude slipped below $110 a barrel amid hopes of US-Iran diplomacy. Separately, Nomura reiterated its Buy rating on IndiGo and raised its target price to Rs 6,200 from Rs 6,000.
Published:
Updated:
What happened
In Monday morning trade, BPCL, HPCL and Asian Paints each gained more than 2%, while IndiGo and SpiceJet also advanced as Brent crude slipped below $110 a barrel amid hopes of US-Iran diplomacy. Separately, Nomura reiterated its Buy rating on IndiGo and raised its target price to Rs 6,200 from Rs 6,000.
Confirmed
Global impact / market context
Cheaper crude can reduce fuel and other oil-based input costs for oil marketing companies, airlines and paint makers, potentially supporting their profit per sale if selling prices do not fall as much. For airlines, lower aviation fuel costs may ease a major operating expense, though the article also cites IndiGo’s ability to pass higher costs to customers.
Analyst inference
The article links the share gains to Brent falling below $110 a barrel amid hopes of a diplomatic breakthrough between the US and Iran. That link suggests investors are responding to expected input-cost relief; it does not establish how long lower crude prices will last or whether the diplomatic outlook will hold.
Analyst inference
What to watch
- Watch whether Brent stays below $110 a barrel and whether US-Iran diplomacy progresses; a reversal in either could change expectations for fuel and input costs. Analyst inference
- Check whether oil marketing companies and paint makers report lower input costs, and whether airlines’ fuel bills ease enough to support operating results. Analyst inference
- Track whether IndiGo can pass higher fuel costs through ticket pricing, as Nomura cited this ability when reiterating Buy and raising its target price. Confirmed
Evidence
- Original source link unavailable